NASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $86.53 +0.32 (+0.37%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Vaxcyte Stock (NASDAQ:PCVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxcyte alerts:Sign Up Key Stats Today's Range$86.25▼$88.9050-Day Range$85.75▼$117.9352-Week Range$53.83▼$121.06Volume3.86 million shsAverage Volume922,601 shsMarket Capitalization$10.78 billionP/E RatioN/ADividend YieldN/APrice Target$145.71Consensus RatingBuy Company OverviewVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More… Vaxcyte Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks32nd Percentile Overall ScorePCVX MarketRank™: Vaxcyte scored higher than 32% of companies evaluated by MarketBeat, and ranked 782nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has only been the subject of 3 research reports in the past 90 days.Read more about Vaxcyte's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.14) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -18.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -18.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.85% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently increased by 13.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.85% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently increased by 13.83%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.60 News SentimentVaxcyte has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Vaxcyte this week, compared to 6 articles on an average week.MarketBeat Follows3 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,383,030.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Stock News HeadlinesInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of StockDecember 20 at 8:30 AM | insidertrades.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 2,366 Shares of StockDecember 11, 2024 | insidertrades.com70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.December 22, 2024 | WealthPress (Ad)Vaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $457,450.00 in StockDecember 10, 2024 | insidertrades.comJim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockDecember 4, 2024 | insidertrades.comVaxcyte’s Promising Pipeline and Strategic Positioning: A Buy Recommendation Amidst Market ChallengesDecember 22 at 5:26 AM | markets.businessinsider.comGoldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Buy RecommendationDecember 21 at 4:50 AM | msn.comVaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia assetDecember 20 at 1:43 PM | msn.comSee More Headlines PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $62.80 at the beginning of the year. Since then, PCVX stock has increased by 37.8% and is now trading at $86.53. View the best growth stocks for 2024 here. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an initial public offering on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Top institutional shareholders of Vaxcyte include FMR LLC (12.68%), Janus Henderson Group PLC (8.76%), RA Capital Management L.P. (6.97%) and Wellington Management Group LLP (3.62%). Insiders that own company stock include Jeff Fairman, Jim Wassil, Grant Pickering, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Halley E Gilbert and Heath Lukatch. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings11/05/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$145.71 High Stock Price Target$163.00 Low Stock Price Target$129.00 Potential Upside/Downside+68.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.53% Return on Assets-22.20% Debt Debt-to-Equity RatioN/A Current Ratio17.88 Quick Ratio17.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book6.64Miscellaneous Outstanding Shares124,637,000Free Float120,773,000Market Cap$10.78 billion OptionableOptionable Beta0.94 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:PCVX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.